A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

Completed · Phase 4

Conditions studied: Stable Coronary Artery Disease

In brief

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic patients with stable coronary artery disease.

Key facts

Study ID

NCT01523366

Run by

AstraZeneca

People needed

53

Starts

2012-04-01

Expected to finish

2013-05-01

Last updated by the study team

2014-08-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of signed and dated informed consent before initiation of any study-related procedures
• Male or female patients aged 18 years or older Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment
• Females must be post menopausal or surgically sterile Self-identified as Hispanic

You may not qualify if…

• Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period
• Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment
• Current smokers, including the use of tobacco containing products in the past 1 month of randomization
• Patients requiring dialysis

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — Hollywood, Florida, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Linden, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.